(Q44956846)

7 December 2017

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway (English)

1 reference

single-nucleotide polymorphism

7 December 2017

1 reference

1 reference

A K Fukunaga

1

1 reference

7 December 2017

S Marsh

2

1 reference

7 December 2017

D J Murry

3

1 reference

7 December 2017

T D Hurley

4

1 reference

7 December 2017

H L McLeod

5

1 reference

7 December 2017

1 January 2004

1 reference

The Pharmacogenomics Journal

7 December 2017

1 reference

7 December 2017

4

1 reference

7 December 2017

5

1 reference

7 December 2017

307-314

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500259

7 December 2017

0 references

cites work

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Caution on pedigree haplotype inference with software that assumes linkage equilibrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Improvements in protein secondary structure prediction by an enhanced neural network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

GOR method for predicting protein secondary structure from amino acid sequence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Pharmacogenomics: unlocking the human genome for better drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Differences in breast cancer stage, treatment, and survival by race and ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Estimates of the worldwide mortality from 25 cancers in 1990.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Thymidylate synthase pharmacogenetics in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

SNP databases and pharmacogenetics: great start, but a long way to go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

Thiopurine methyltransferase alleles in British and Ghanaian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

7 January 2021

2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

7 January 2021

Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

7 January 2021

Novel thymidylate synthase enhancer region alleles in African populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

7 January 2021

Pharmacogenetics and cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

7 January 2021

Monte Carlo tests for associations between disease and alleles at highly polymorphic loci

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500259

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500259

1 reference

Dimensions Publication ID

7 December 2017

0 references

1 reference